| Objectives: To explore the protective effect of recombinant human erythropoietin (rhEPO) on hepatic ischemia reperfusion injury in rats and its suitable dosage and timing, and To explore the effect of specific inhibition of NF-κB after ischemia reperfusion injury.Methods: Eighty-four Wistar rats were randomly divided into seven groups:control group (group A, n =12), rhEPO pretreatment groups (groups B, C, D, E, F and G, n=12 in each group). Liver pedicles were occluded in group A, in group B, C and D, rhEPO was administrated 5000U/Kg intraperitoneal daily for 3d, 30min and 5min before ischemia, respectively. In groupE, F and G, rhEPO was administrated 1000U/Kg intraperitoneal daily for 3d, 30min and 5min before ischemia, respectively. After 45 min ischemia and 2 h reperfusion,the rats were killed. Serum aspartic acid aminotransferase(AST) , alanine aminotransferase (ALT), tumor necrosis factor-α(TNF-α) and interleukin-1β(IL-1β) were measured, and liver histopathology was observed by H.E staining. Nuclear factor-κB(NF-κB) was detected by immunohistochemistry, and apoptotic index(AI) was calculated by TUNEL assay.Results: The parenchymal hepatic cell necrosis and structure derangement of hepatic lobules in pretreatment groups were lighter than in group A. However, hepatic cell necrosis were the most lightest in group F. Compared with group A, serum AST, ALT, TNF-αand IL-1βwere all significantly decreased (P< 0.05), NF-κB was significantly higher in pretreatment groups than in group A (P<0.01), and AI was significantly lower in pretreatment groups than in group A (P< 0.05), however, there was the most different compared with group F (P<0.01).Conclusions: RhEPO could protect the liver from ischemia reperfusion injury in rats, hypo-dosage(1000U/Kg)and pretreatment before 30 min ischemia is optimal, specific inhibition of apoptosis NF-κB reduces effectively hepatic cell ischemia reperfusion injury.
|
PDF Full Text Request